



Patent Application
Attorney Docket No. PC23015A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450 on this 14th day of January 2004

By

Irene Grantham

(Signature of person mailing)

Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Marcus E. Kehrli, Jr. :

APPLICATION NO.: 10/626,826 : Examiner: To Be Assigned

FILING DATE: July 22, 2003 : Group Art Unit: To Be Assigned

TITLE: METHODS FOR ENHANCING IMMUNE :
FUNCTIONS IN NEONATAL MAMMALS BY
ADMINISTRATION OF IL-18

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: Jan 13, 2004
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Respectfully submitted,
Martha G. Munchhof
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC23015A					SERIAL NO. 10/626,826				
										APPLICANT Marcus E. Kehrl, Jr.									
										FILING DATE July 22, 2004					GROUP To Be Assigned				
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER								DATE		NAME		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER										DATE		COUNTRY		CLASS		SUBCLASS		TRANSLATION	
																		YES NO	
		WO	9	9	6	6	8	7	9	12/29/99	Int'l		A61K						
		WO	0	1	0	4	2	7	1	1/18/01	Int'l		C12N		7/00				
		WO	0	1	9	3	8	9	8	12/13/01	Int'l		A61K		38/19				
		EP	1	0	9	5	6	6	1	5/2/01	EP		A61K		38/20				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
		Suri Mandhir, et al., "Prohylactic Single and Sequential Cytokines (M-CSF, IL-12, IL-18) in comination with Antibiotics (Ab) Significantly Enhances Survival During Experimental Neonatal Murine Listeriosis: Implications for Enhancing Neonatal Immunity", <u>Pediatric Research</u> 53(4/2), p. 309A (2003), XP0009020958																	
		Mastroeni, et al., "Interleukin 18 Contributes to Host Resistance and Gamma Interferon Production in Mice Infected with Virulent <i>Salmonella typhimurium</i> ", <u>Infection and Immunity</u> 67(2), p. 478-483 (1999), XP-002964670																	
		Dupre, et al., "Immunostimulatory effect of IL-18-encoding plasmid in DNA vaccination against murine <i>Schistosoma mansoni</i> infection", <u>Vaccine</u> 19, pp. 1373-1380 (2001), XP-4313950A																	
		Muneta, et al., "Expression of Interleukin-18 by Procine Airway and Intestinal Epithelium", <u>Journal of Interferon and Cytokine Research</u> 22, pp. 883-889 (2002)																	
		La Pine, et al., "Priming Neonatal Mononuclear Cells with the Th-1 Cytokines IL-18 and IL-12 Corrects Defective Interferon- γ Production in Response to Group B Streptococci", <u>Pediatric Research</u> 51(4/2), p. 324A (2002), XP009020957																	
EXAMINER										DATE CONSIDERED									
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																			